CQS New City High Yield Fund Umsatz
Was ist das Umsatz von CQS New City High Yield Fund?
Umsatz von CQS New City High Yield Fund Ltd. ist £8.238M
Was ist die Definition von Umsatz?
Umsatz sind die Einnahmen, die ein Unternehmen aus seiner normalen Geschäftstätigkeit erzielt, normalerweise aus dem Verkauf von Waren und Dienstleistungen an Kunden.
Revenue is also referred to as sales or turnover. Some companies receive revenue from interest, royalties, or other fees. Revenue may refer to business income in general, or it may refer to the amount, in a monetary unit, earned during a period of time, as in "Last year, Company X had revenue of $42 million". Profits or net income generally imply total revenue minus total expenses in a given period.
In accounting, revenue is often referred to as the "top line" due to its position on the income statement at the very top. This is to be contrasted with the "bottom line" which denotes net income.
Umsatz von Unternehmen in Finance Sektor auf LSE im Vergleich zu CQS New City High Yield Fund
Was macht CQS New City High Yield Fund?
CQS New City High Yield Fund Limited is a close ended fixed income mutual fund launched by CQS Asset Management Ltd. The fund is managed by CQS (UK) LLP. It invests in fixed income markets. The fund primarily invests in fixed income securities such as corporate and government bonds, loan stocks, and high yielding bonds. It uses a value approach to create its portfolio. The fund was formerly known as New City High Yield Fund Limited. CQS New City High Yield Fund Limited was formed in October 2004 and is domiciled in the Channel Islands.
Unternehmen mit umsatz ähnlich CQS New City High Yield Fund
- Spectur hat Umsatz von AUD$8.180M
- Ocugen Inc hat Umsatz von $8.191M
- Safe & Green Corp hat Umsatz von $8.193M
- Timah Resources hat Umsatz von RM8.200M
- cyan AG hat Umsatz von €8.200M
- Mereo BioPharma plc hat Umsatz von £8.231M
- CQS New City High Yield Fund hat Umsatz von £8.238M
- InCity Immobilien AG hat Umsatz von €8.275M
- Ariadne Australia hat Umsatz von AUD$8.280M
- Dev Clever Plc hat Umsatz von £8.284M
- Cue Biopharma Inc hat Umsatz von $8.296M
- Celldex Therapeutics hat Umsatz von $8.302M
- RAS Technology Ltd hat Umsatz von AUD$8.328M